Department of Neurosurgery, Seoul National University Hospital, Seoul, Republic of Korea.
Gamma Knife Radiosurgery Center, Seoul National University Hospital, Seoul, Republic of Korea.
Sci Rep. 2023 Aug 12;13(1):13159. doi: 10.1038/s41598-023-40356-6.
Gamma Knife surgery (GKS) for brain metastasis (BM) has been generally advocated for patients with a Karnofsky performance status (KPS) scale of ≥ 70. However, some patients with a poor KPS scale of < 70 are recoverable after GKS and show durable survival. A purpose of this study is to devise a 3-month survival prediction model to screen patients with BM with a KPS of ≤ 70 in whom GKS is needed. A retrospective analysis of 67 patients with a KPS scale of 60-70 undergoing GKS for BM of non-small cell lung cancer (NSCLC) from 2016 to 2020 in our institute was performed. Univariate and multivariate logistic regression analyses were performed to investigate factors related to survival for more than 3 months after GKS. The probability (P) prediction model was designed by giving a weight corresponding to the odds ratio of the variables. The overall survival was 9.9 ± 12.7 months (range 0.2-53.2), with a 3-month survival rate of 59.7% (n = 40). In multivariate logistic regression analysis, extracranial disease (ECD) control (p = .033), focal neurological deficit (FND) (p = .014), and cumulative tumor volume (∑ TV) (p = .005) were associated with 3-month survival. The prediction model of 3-month survival (Harrell's C index = 0.767) was devised based on associated factors. In conclusion, GKS for BMs is recommended in selected patients, even if the KPS scale is ≤ 70.
伽玛刀手术(GKS)已普遍被推荐用于卡氏功能状态评分(KPS)≥70 的脑转移瘤(BM)患者。然而,一些 KPS 评分<70 的患者在接受 GKS 治疗后可恢复,且生存时间持久。本研究的目的是制定一个 3 个月生存预测模型,以筛选需要 GKS 治疗的 KPS 评分≤70 的 BM 患者。回顾性分析了 2016 年至 2020 年我院 67 例 KPS 评分为 60-70 的非小细胞肺癌(NSCLC)脑转移患者接受 GKS 治疗的资料。采用单因素和多因素逻辑回归分析探讨 GKS 后 3 个月以上生存相关因素。根据变量的比值比,设计概率(P)预测模型,并赋予相应的权重。总体生存时间为 9.9±12.7 个月(范围 0.2-53.2),3 个月生存率为 59.7%(n=40)。多因素逻辑回归分析显示,颅外疾病(ECD)控制(p=0.033)、局灶性神经功能缺损(FND)(p=0.014)和累积肿瘤体积(∑TV)(p=0.005)与 3 个月生存率相关。根据相关因素制定了 3 个月生存预测模型(Harrell's C 指数=0.767)。总之,即使 KPS 评分≤70,也推荐对选定的 BM 患者行 GKS 治疗。